News

PharmExec1d
Roche’s Lunsumio-Polivy Combo Significantly Improves Outcomes in Relapsed or Refractory Large B-Cell Lymphoma
Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...
Fierce Pharma3d
Roche's bispecific-ADC combo keeps cancer at bay in 2nd shot at 2nd-line large B-cell lymphoma
Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...
Clinical Trials Arena3d
Roche and Genentech’s Lunsumio-Polivy shows promise in Phase III trial
Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial.
The Pharma Letter3d
Positive new data on Roche’s Lunsumio and Polivy combo
Swiss pharma giant Roche has released encouraging results from the Phase III SUNMO study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin), ...
The Manila Times3d
Early data suggest Roche's NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, ...
Roche's Genentech reports positive results from lymphoma trial
Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...
lupus.bmj6d
178 Phase 2 trial of induction therapy with anti-CD20 (Rituximab) followed by maintenance therapy with anti-BAFF (Belimumab) in patients with active lupus nephritis
Background Despite case series suggesting efficacy, controlled trials of anti-CD20 in lupus and lupus nephritis (LN) have not meet their primary endpoints (Arthritis Rheum 2012;64:1215 and ...